Skip to content

Unda: what changed

BE 0403.987.182NACE 21.201, Manufacture of basic pharmaceutical products and pharmaceutical preparationsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
€61,912
2024 · -€28,705+€90,616
Equity
€486,787
2024 · €424,875+€61,912
Cash
-
not filed
Balance sheet total
€517,605
2024 · €473,026+€44,579

Largest movements

2024 to 2025
Assets
  • Financial fixed assets +€90,509

    up €90,509 (+1,627%), from €5,563 to €96,072

  • Receivables within one year -€45,930

    down €45,930 (-9.8%), from €467,463 to €421,533

    of which Other amounts receivable: -€42,572

Equity and liabilities
  • Profit (loss) carried forward +€61,912

    up €61,912 (+31.4%), from -€197,016 to -€135,104

  • Trade debts -€16,978

    down €16,978 (-53.9%), from €31,507 to €14,529

Income statement
  • Gross operating margin +€98,214

    up €98,214, from -€44,286 to €53,928

  • Financial income -€7,734

    down €7,734 (-45.6%), from €16,968 to €9,234

    of which Financial income: -€7,734

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 -€28,705
Gross operating margin +€98,214
Other operating charges +€528
Financial income -€7,734
Financial charges -€392
Result 2025 €61,912
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

Cash or the result is not a separate line in both sets of accounts. So the cash flow cannot be derived from them.

Every line side by side 42 lines
Line Code 2024 2025 Change %
Total assets 20/58 €473,026 €517,605 +€44,579 +9.4%
Fixed assets 21/28 €5,563 €96,072 +€90,509 +1,627%
Financial fixed assets 28 €5,563 €96,072 +€90,509 +1,627%
Current assets 29/58 €467,463 €421,533 -€45,930 -9.8%
Amounts receivable within one year 40/41 €467,463 €421,533 -€45,930 -9.8%
Trade receivables 40 €6,053 €2,695 -€3,358 -55.5%
Other amounts receivable 41 €461,410 €418,837 -€42,572 -9.2%
Total equity and liabilities 10/49 €473,026 €517,605 +€44,579 +9.4%
Equity 10/15 €424,875 €486,787 +€61,912 +14.6%
Contributions 10/11 €61,500 €61,500 = 0.0%
Capital 10 €61,500 €61,500 = 0.0%
Issued capital 100 €61,500 €61,500 = 0.0%
Reserves 13 €560,391 €560,391 +€0 0.0%
Non-distributable reserves 130/1 €7,354 €7,354 -€0 0.0%
Legal reserve 130 €6,150 €6,150 = 0.0%
Other 1319 €1,204 €1,204 -€0 0.0%
Tax-exempt reserves 132 €109,413 €109,414 +€1 0.0%
Distributable reserves 133 €443,624 €443,624 -€0 0.0%
Profit (loss) carried forward 14 -€197,016 -€135,104 +€61,912 +31.4%
Amounts payable 17/49 €48,150 €30,818 -€17,333 -36.0%
Amounts payable within one year 42/48 €48,097 €30,818 -€17,280 -35.9%
Trade debts 44 €31,507 €14,529 -€16,978 -53.9%
Suppliers 440/4 €31,507 €14,529 -€16,978 -53.9%
Taxes, remuneration and social security 45 €302 €0 -€302 -100%
Taxes 450/3 €84 €0 -€84 -100%
Remuneration and social security 454/9 €218 - -€218
Other amounts payable 47/48 €16,289 €16,289 -€0 0.0%
Accrued charges and deferred income 492/3 €53 €0 -€53 -100%
Non-recurring operating income 76A - €90,509 +€90,509
Remuneration, social security and pensions 62 €0 - =
Provisions for liabilities and charges: additions (uses and reversals) 635/8 €0 - =
Other operating charges 640/8 €528 €0 -€528 -100%
Gross operating margin 9900 -€44,286 €53,928 +€98,214
Operating profit (loss) 9901 -€44,814 €53,928 +€98,742
Financial income 75/76B €16,968 €9,234 -€7,734 -45.6%
Recurring financial income 75 €16,968 €9,234 -€7,734 -45.6%
Non-recurring financial income 76B - €0 =
Financial charges 65/66B €859 €1,251 +€392 +45.6%
Recurring financial charges 65 €859 €1,251 +€392 +45.6%
Profit (loss) for the period before taxes 9903 -€28,705 €61,912 +€90,616
Profit (loss) for the period 9904 -€28,705 €61,912 +€90,616
Profit (loss) for the period to be appropriated 9905 -€28,705 €61,912 +€90,616

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€396,797 to €458,159

Midpoint €422,365 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years, excluding non-recurring income and charges earnings weight 50%

Worked out with Checked's starting values, not your estimate and not market data. Change the assumptions: the value follows.

Adjusted equity €486,787
Capitalised earnings €306,807 to €429,530
Indication €396,797 to €458,159

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€486,787
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€486,787

Capitalised earnings

net result for the year (9904)
2025
€61,912
excluding non-recurring income and charges
-€28,598
2024
-€28,705
2023
€186,161
2022
-€61,225
2021
€3,289
Average result, excluding non-recurring income and charges
€42,953
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€306,807 / €357,942 / €429,530

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 17 November 2026 via checked.be.